HUNTSVILLE, Ala. — Serina Therapeutics, Inc., a pharmaceutical research and development company, announced the company was awarded two patents from the United States Patent and Trademark Office covering its polymer technology.
The patents entitled “Multi-armed forms of activated polyoxazoline and methods of synthesis thereof” (U.S. Patent No. 8,088,884) and “Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same” (U.S. Patent No. 8,110,651) cover the synthesis and composition of new scaffolds of polyoxazolines for the delivery of different types of drug molecules.
“These additional patent awards strengthen our polymer drug delivery platforms and add intellectual property support to our lead candidates currently in drug development,” said Michael D. Bentley, Ph.D., chief scientific officer and cofounder of the company.
The issue of these two patents is the result of years of groundbreaking research in the development of safe polyoxazoline polymers for drug delivery.
“We are now in a position to add to our strong pipeline of polymer therapeutic molecules,” said Bentley.
For more information on Serina Therapeutics, please visit serinatherapeutics.com
About Serina: Serina Therapeutics is a privately held pharmaceutical company that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled nine approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs. Serina Therapeutics is located with the HudsonAlpha Institute for Biotechnology in Huntsville, Ala.
Media Contact: Beth Pugh
bpugh@hudsonalpha.org
256-327-0443
About HudsonAlpha: HudsonAlpha Institute for Biotechnology is a nonprofit institute dedicated to innovating in the field of genomic technology and sciences across a spectrum of biological problems. Its mission is three-fold: sparking scientific discoveries that can impact human health and well-being; fostering biotech entrepreneurship; and encouraging the creation of a genomics-literate workforce and society. The HudsonAlpha biotechnology campus consists of 152 acres nestled within Cummings Research Park, the nation’s second largest research park. Designed to be a hothouse of biotech economic development, HudsonAlpha’s state-of-the-art facilities co-locate scientific researchers with entrepreneurs and educators. The relationships formed on the HudsonAlpha campus allow serendipity to yield results in medicine and agriculture. Since opening in 2008, HudsonAlpha, under the leadership of Dr. Richard M. Myers, a key collaborator on the Human Genome Project, has built a name for itself in genetics and genomics research and biotech education, and boasts 26 biotech companies on campus.
